Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorBEURTON, Antoine
dc.contributor.authorMANSOUR, Alexandre
dc.contributor.authorBENARD, Antoine
dc.contributor.authorPERNOT, Mathieu
dc.contributor.authorBRETT, Victor-Emmanuel
dc.contributor.authorBATSALE, Corinne
dc.contributor.authorAITGOUGAM, Anais
dc.contributor.authorCORDON, Anais
dc.contributor.authorMOUTON, Christine
dc.contributor.authorFRESSELINAT, Aurelie
dc.contributor.authorROBERT, Geraldine
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorIMBAULT, Julien
dc.contributor.authorNESSELER, Nicolas
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorOUATTARA, Alexandre
dc.date.accessioned2025-09-01T07:26:31Z
dc.date.available2025-09-01T07:26:31Z
dc.date.issued2025-07-16
dc.identifier.issn2044-6055en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/207533
dc.description.abstractEnCardiac surgery remains a high-risk procedure for bleeding despite advances in patient blood management. Conventional centrifugation-based autotransfusion devices primarily recover red blood cells, losing platelets and coagulation factors. The SAME autotransfusion device (i-SEP, Nantes, France) introduces an innovative filtration-based approach, recovering erythrocytes, leucocytes and platelets to enhance perioperative haemostasis. The main objective is to determine whether the filtration-based SAME device reduces significant perioperative bleeding compared with the centrifugation-based system in high-risk cardiac surgery patients. The Centrifugation-based vs filtration-based intraOperative cell saLvage on qualiTy of peRioperAtive haemostasis iN cardiac surgEry (COLTRANE) trial is a multicentre, parallel-group, single-blinded, superiority-randomised clinical trial. Conducted over 19 months in 10 French hospitals, the study will target patients at high risk of bleeding undergoing on-pump cardiac surgery via sternotomy. A total of 570 patients (285 per group) are required to achieve 80% statistical power for detecting clinically significant differences. Eligible patients will be randomised to either a centrifugation-based or filtration-based autotransfusion group. Both groups will follow standardised perioperative and cardiopulmonary bypass management, with the devices used only intraoperatively. The primary outcome is the proportion of patients with clinically significant perioperative bleeding defined as classes 2 to 4 of the Universal Definition of Perioperative Bleeding. The secondary outcomes include device efficiency and safety, perioperative haemostasis, lengths of intensive care unit and hospital stays, early postoperative morbidity and 30-day all-cause mortality. Ancillary studies will be performed to evaluate cell recovery and washing performance, the viscoelastic properties of retransfused blood (Quantra Qplus; Stago, Asnières-sur-Seine, France), and the effect of salvaged leucocytes on postoperative inflammation and immune function. This trial has received a favourable opinion from the Committee for the Protection of Persons and authorisation from the French authorities (Comité de protection des personnes Nord Ouest, IDRCB: 2023-A02566-39). Protocol V.1.1 was approved on 22 January 2024. The trial is registered on ClinicalTrials.gov (NCT06425614). The findings will be disseminated through oral communications at national and international scientific meetings and peer-reviewed journal publications. Individual participant data will be made available on reasonable request to qualified researchers, following review and approval by the study sponsor and ethics committee. ClinicalTrials.gov, NCT06425614.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enHumans
dc.subject.enCardiac Surgical Procedures
dc.subject.enCentrifugation
dc.subject.enOperative Blood Salvage
dc.subject.enFiltration
dc.subject.enBlood Transfusion
dc.subject.enAutologous
dc.subject.enSingle-Blind Method
dc.subject.enRandomized Controlled Trials as Topic
dc.subject.enMulticenter Studies as Topic
dc.subject.enFrance
dc.subject.enBlood Loss
dc.subject.enSurgical
dc.title.enCentrifugation versus filtration-based cell salvage: impact on perioperative bleeding in cardiac surgery-the COLTRANE randomised clinical trial - study protocol.
dc.title.alternativeBMJ Openen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1136/bmjopen-2025-099423en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed40669902en_US
bordeaux.journalBMJ Openen_US
bordeaux.pagee099423en_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue7en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-05232325
hal.version1
hal.date.transferred2025-09-01T07:26:35Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMJ%20Open&rft.date=2025-07-16&rft.volume=15&rft.issue=7&rft.spage=e099423&rft.epage=e099423&rft.eissn=2044-6055&rft.issn=2044-6055&rft.au=BEURTON,%20Antoine&MANSOUR,%20Alexandre&BENARD,%20Antoine&PERNOT,%20Mathieu&BRETT,%20Victor-Emmanuel&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée